Eli Lilly and Co (LLY)

LLY (NYSE:Drugs)
$57.50
neg -2.06
-3.46%
Today's Range: 57.35 - 59.18 | LLY Avg Daily Volume: 5,404,100
Last Update: 04/24/14 - 10:26 AM EDT
Volume: 1,829,306
YTD Performance: 16.78%
Open: $58.31
Previous Close: $59.56
52 Week Range: $47.53 - $61.15
Oustanding Shares: 1,119,713,084
Market Cap: 67,219,029,999
6-Month Chart
TheStreet Ratings Grade for LLY
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 6 4 5 5
Moderate Buy 0 0 0 0
Hold 6 5 6 5
Moderate Sell 0 1 1 1
Strong Sell 2 3 2 3
Mean Rec. 2.38 2.87 2.59 2.74
Latest Dividend: 0.49
Latest Dividend Yield: 3.30%
Dividend Ex-Date: 02/12/14
Price Earnings Ratio: 13.75
Price Earnings Comparisons:
LLY Sector Avg. S&P 500
13.75 13.90 29.23
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
8.00% 2.11% 64.26%
GROWTH 12 Mo 3 Yr CAGR
Revenue 2.30 0.00 0.00
Net Income 14.60 -0.08 -0.03
EPS 18.00 -0.05 -0.02
Earnings for LLY:
EBITDA 6.99B
Revenue 23.11B
Average Earnings Estimates
Qtr (03/14) Qtr (06/14) FY (12/14) FY (12/15)
Average Estimate $0.70 $0.65 $2.81 $3.14
Number of Analysts 9 8 10 11
High Estimate $0.76 $0.69 $2.84 $3.45
Low Estimate $0.62 $0.58 $2.76 $2.78
Prior Year $1.14 $1.16 $4.15 $2.81
Growth Rate (Year over Year) -38.30% -43.86% -32.41% 11.78%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands

bearishEli Lilly downgraded at Leerink

Apr 23, 2014 | 7:51 AM EDT

LLY was downgraded from Buy to Neutral, Leerink Swann said. $61 price target. Company lacks near-term catalysts and made an expensive acquisition of Novartis' animal health business.

bullishEli Lilly price target, EPS bumped up at Jefferies

Apr 23, 2014 | 7:28 AM EDT

LLY raised its numbers, Jefferies said. Driven by accretive NAH acquisition. $60 price target and Hold rating. 

By

Paul Curcio

 | Apr 22, 2014 | 9:00 AM EDT

Futures point higher; blockbuster drug deal boosts European markets.

updateEli Lilly upgraded at Jefferies

Apr 14, 2014 | 7:54 AM EDT

LLY upgraded to Hold from Underperform, Jefferies said. Material downside catalysts removed. $54 price target. 

bullishEli Lilly upgraded at BMO

Apr 8, 2014 | 8:01 AM EDT

LLY was upgraded from Underperform to Market Perform, BMO Capital said. $62 price target. Company has been executing well, versus low expectations. 

By

Jim Cramer

 | Mar 29, 2014 | 8:00 AM EDT

TheStreet's Jim Cramer says newer pharmaceutical companies, like Celgene (CELG), Isis Pharmaceuticals (ISIS) and Seattle Genetics (SGEN), should be bought on any weakness because they have the potential to perform extremely well and may be better buys than Pfizer, Merck, Bristol-Myers and Eli Lilly.

By

Gary Morrow

 | Feb 19, 2014 | 1:22 PM EST

And the stock now has layers of support in place.

bullishEli Lilly price target bumped at Jefferies

Feb 12, 2014 | 8:15 AM EST

ELI raised its number, Jefferies said. Strong performance in Cymbalta, Humalog, Alimta, and Cialis. $44 price target and Underperform rating. 

bearishLeerink Healthcare Conf.

Feb 12, 2014 | 7:10 AM EST

Leerink Swann Global Healthcare Conference (Day 1 of 2) - 02/12/14 - 02/13/14 New York, NY

By

Christopher Versace

 | Feb 11, 2014 | 11:00 AM EST

Medidata Solutions is focusing its cloud-computing offerings on the pharmaceutical industry.

General Electric dipped down to key nearby support during the early stock sell off. ...
Apple (APPL) has been trading for over a year within the parameters of a set Fibonacci ret...
Some days an investor is the bug some days he is the windshield. It is nice to start the ...
Just a week ago I mentioned here on the CC that we bought the May 525 AAPL call for 12 buc...

REAL MONEY PRO'S BEST IDEAS

Columnist Tweets

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.